The call highlighted significant progress in clinical trials and pipeline expansion, alongside strategic moves in manufacturing readiness and financial planning. However, these were tempered by declines in revenue and increased expenses, alongside some regulatory and financial uncertainties.

Company Guidance

During the Longeveron 2025 Q2 Financial Results and Business Update Call, significant guidance was provided on the company's strategic focus and financial status. The company is targeting three main operational goals for 2025: advancing the ELPIS II pivotal Phase 2b study for Hypoplastic Left Heart Syndrome (HLHS), preparing for the Biologics License Application (BLA) submission, and pursuing strategic collaborations for their Alzheimer’s disease program. The HLHS program is prioritized due to its high probability of success and shorter regulatory path. Longeveron has completed enrollment for the ELPIS II Phase 2b study with 40 patients, anticipating top-line results by Q3 2026. Financially, the company reported a decrease in revenue to $0.7 million for the first half of 2025, down from $1 million in 2024, and a net loss of $10 million compared to $7.5 million the previous year. This is attributed to increased general and administrative expenses and research and development costs, primarily due to personnel and manufacturing readiness activities. With cash and cash equivalents of $10.3 million as of June 30, 2025, and a recent public offering raising approximately $5 million, Longeveron expects to fund operations into Q1 2026, contingent on securing additional financing.

Completion of ELPIS II Phase 2b Enrollment

Longeveron completed enrollment for the pivotal ELPIS II Phase 2b study, evaluating laromestrocel as a treatment for HLHS, a significant step towards regulatory approval.

Positive Regulatory Progress

The FDA's determination that ELPIS II is pivotal accelerates the regulatory path for laromestrocel, with a potential rolling BLA submission in late 2026.

Strong Pipeline Expansion

Introduction of pediatric dilated cardiomyopathy to the pipeline, with an IND approval from the FDA for a Phase 2 pivotal trial, showing confidence in the program.

Strategic Manufacturing Partner

Decision to use a third-party CDMO for commercial manufacturing to leverage scale and experience, facilitating the strategic plan for BLA readiness.

Positive Financial Outlook

Completion of a public offering raising approximately $5 million with potential for an additional $12.5 million, ensuring funding into the first quarter of 2026.

Longeveron (LGVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LGVN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2025 (Q3)	-0.26 / -	-0.34	―	―	―
Aug 13, 2025	2025 (Q2)	-0.35 / -0.33	-1.83	81.97% (+1.50)	―
May 08, 2025	2025 (Q1)	-0.33 / -0.34	-1.61	78.88% (+1.27)
Feb 28, 2025	2024 (Q4)	-0.37 / -0.43	-2.5	82.64% (+2.07)
Nov 12, 2024	2024 (Q3)	-0.39 / -0.34	-2.8	87.86% (+2.46)	―
Aug 14, 2024	2024 (Q2)	-1.12 / -1.83	-2.7	32.22% (+0.87)	―
May 14, 2024	2024 (Q1)	-2.00 / -1.61	-2.2	26.82% (+0.59)	―
Feb 27, 2024	2023 (Q4)	-2.13 / -2.50	-2.1	-19.05% (-0.40)	―
Nov 10, 2023	2023 (Q3)	-2.25 / -2.80	-2.5	-12.00% (-0.30)	―	―
Aug 11, 2023	2023 (Q2)	-2.47 / -2.70	-2.7	0.00% (0.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LGVN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.86	$0.76	-11.63%
May 08, 2025	$1.49	$1.34	-10.07%
Feb 28, 2025	$1.52	$1.38	-9.21%
Nov 12, 2024	$2.30	$2.12	-7.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Longeveron (LGVN) report earnings?

Longeveron (LGVN) is schdueled to report earning on Nov 07, 2025, Before Open (Confirmed).

What is Longeveron (LGVN) earnings time?

Longeveron (LGVN) earnings time is at Nov 07, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LGVN EPS forecast?

LGVN EPS forecast for the fiscal quarter 2025 (Q3) is -0.26.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing